Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Irvin Chen

University of California Los Angeles, Department: Microbiology/immun/virology

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Calimmune

Disclosed Value
Listed Reason
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)

Professor Chen is the PI and will provide overall design and guidance for this project and for the overall program. He is a company founder and research advisor. Per Dr. Chen, "sh1005, shRNA to CCR5, licensed by Calimmune, will be used. It will not in itself be further developed, but will be combined with other reagents including chimeric antigen receptors" and "CARS may be further developed in the project".

Listed Research Project
Anti-HIV Gene Therapy: Defend and Attack

We propose to develop a therapy where blood stem cells and T-cells are modified to both resist HIV-1 infection and to kill HIV infected cells. Project 1: Improve the engraftment of combinatorial anti-HIV-1 gene modified HSPC Project Leader (PL): Dong Sung An DESCRIPTION (as provided by applicant): Our overall goal in this proposal is to improve engraftment of anti-HIV gene modified hematopoietic stem/progenitor cells (HSPC) in vivo. HSPC based gene therapy holds great promise to provide long-term protection against HIV with the possibility of achieving a cure. However, studies to date have met with limited success largely due to the low efficiency of gene delivery into HSPC and subsequent hematopoietic reconstitution with anti-HIV gene modified cells. Overall we hypothesize that the efficiency of repopulation is important for the efficacy of HSPC-based gene therapy as apparent for the first case of HIV cure that was recently achieved by nearly complete bone marrow replacement by CCR5 deficient transplanted donor cells. However, unlike the first case of the HIV cured patient, complete bone marrow replacement by gene modified HSPC may not occur because of the limited efficiency of anti-HIV gene modified HSPC engraftment. Additionally, use of the intensive myeloablation procedure because of the presence of leukemia allowed in this first case of an HIV cure poses a high risk clinically. Therefore, in order to provide clinical benefit by HSPC gene therapy strategies, research is required to achieve more effective and safe procedures that can provide positive selection of genetically modified HSPC in patients. In this proposal, we will test a novel in vivo selection strategy that exclusively employs 6-thioguanine for both pre-conditioning and chemoselection of HPRT down-regulated genetically engineered HSPC, that is capable of enriching engraftment and long-term reconstitution of genetically engineered multi-pronged HIV resistant HSPC and progenies using a HIV infection established humanized mouse model. Our proposed research has a potential to break through the major obstacle in the field for HSPC gene therapy to enrich and efficiently repopulate gene-modified cells for the successful control of HIV disease without life long drug treatment and for HIV cure.

Filed on May 27, 2015.

Tell us what you know about Irvin Chen's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

Name Institution Type Company Disclosed Value
Irvin Chen University of California Los Angeles Conflict of Interest Calimmune (Aquired by CSL Behring) $550,000 - $599,999
Irvin Chen University of California Los Angeles Conflict of Interest Calimmune $350,000 - $399,999
Irvin Chen University of California Los Angeles Conflict of Interest Calimmune Value cannot be readily determined
Irvin Chen University of California Los Angeles Conflict of Interest Calimmune Value cannot be readily determined
Irvin Chen University of California Los Angeles Conflict of Interest Calimmune (Aquired by CSL Behring) Value cannot be readily determined
If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page